Session: LBA02: Late-Breaking Abstracts II - Cancer
LBA02-12: Is learning curve important while performing PSMA-PET? Analysis of detection rate according to Gleason score and PSA level in two timeframes at a Brazilian high-volume center
Introduction: PSMA PET/CT scan (68Ga-PSMA PET/CT) has emerged as a highly accurate method for assessing disease staging in patients with newly diagnosed localized high-risk prostate cancer and for recurrent disease. This has resulted in treatment plan modification in up to two-thirds of patients. PSMA PET/CT is commercially available in Brazil for a decade and growing experience with this test has led to more precise results over the years. Methods: We retrospectively reviewed the results of PSMA PET/CT scans performed on patients at all disease stages in a single institution in Brasilia from 2015-2018 and 2021-2022. The results were correlated with available clinicopathological information in patients with recurrent disease in two separated timeframes. Results: From 2015-2019, 351 exams were performed, with 303 in the setting of recurrent disease. From 2021-2022, 297 tests were executed with 283 in the recurrent disease setting. Clinicopathological information was available for 648 patients, with 586 patients in the setting of recurrent disease after first line treatment. PSA level (ng/mL) Gleason Score Detection Rate (2015-2018) Detection Rate (2021-2022) 0-0.5 = 3+4 5/21 (24%) 15/37 (40%) = 4+3 9/16 (56%) 20/39(51%) 0.51-1.0 = 3+4 2/9 (22%) 02/02 (100%) = 4+3 8/10 (80%) 05/06 (83%) 1.0-2.0 = 3+4 5/7 (71%) 07/09 (77%) = 4+3 7/7 (100%) 07/08 (87.5%) >2.0 = 3+4 17/18 (94%) 20/22 (90%) = 4+3 26/26 (100%) 17/18 (94.4%) Conclusions: There was a clinically relevant increase in the detection rate for patients with PSA = 0.5 ng/mL and Gleason score =3+4, possibly as a result of the learning curve for this challenging scenario. However, we found a similar detection rate among other clinicopathological characteristics. Our data supports the need for ongoing training for the analysis of PSMA PET/CT results. SOURCE OF Funding: the authors
